Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Stereotactic ablative radiotherapy for patients during COVID-19 pandemic

In June 2020, NHS England announced in June 2020 that it is accelerating the use of stereotactic ablative radiotherapy (SABR) requiring fewer doses than standard radiotherapy, decreasing the number of hospital visits that potentially vulnerable patients need to undergo. It will now be available through the NHS by the end of the current financial year, rather than full rollout by 2022.

It is a very accurate method of using a high dose of radiation with only about five outpatient visits compared to conventional radiotherapy, requiring between 20 and 30 treatments.

SABR treatment for non-small cell lung cancer and those with lung, lymph nodes, and non-spine bone oligometastatic disease will be offered to all parts of the country in radiotherapy units nationwide. A further rollout for other types of diseases is planned for 2021/22.

See the full details here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.